NCT06866912 Observational Epidemiological Study of Patients Suffering From Systemic Amyloidosis
| NCT ID | NCT06866912 |
| Status | Recruiting |
| Phase | — |
| Sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna |
| Condition | Cardiomyopathy |
| Study Type | OBSERVATIONAL |
| Enrollment | 750 participants |
| Start Date | 2023-09-01 |
| Primary Completion | 2033-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 750 participants in total. It began in 2023-09-01 with a primary completion date of 2033-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
observational epidemiological study of patients affected by systemic amyloidosis
Eligibility Criteria
Inclusion Criteria: * patients diagnosed with amyloidosis or asymptomatic carriers of mutations in the transthyretin gene * minimum age of 18 years at the time of diagnosis * obtaining informed consent Exclusion Criteria: * nothing
Contact & Investigator
Simone Longhi, MD
PRINCIPAL INVESTIGATOR
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Frequently Asked Questions
Who can join the NCT06866912 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 99 Years, studying Cardiomyopathy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06866912 currently recruiting?
Yes, NCT06866912 is actively recruiting participants. Contact the research team at simone.longhi@aosp.bo.it for enrollment information.
Where is the NCT06866912 trial being conducted?
This trial is being conducted at Bologna, Italy.
Who is sponsoring the NCT06866912 clinical trial?
NCT06866912 is sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna. The principal investigator is Simone Longhi, MD at IRCCS Azienda Ospedaliero-Universitaria di Bologna. The trial plans to enroll 750 participants.